University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan
|
|
- Baldwin Dawson
- 5 years ago
- Views:
Transcription
1 University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2016 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Mihajlovic, J. (2016). Health economics of targeted therapies: A comparative analysis for Serbia and the Netherlands. [Groningen]: Rijksuniversiteit Groningen. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date:
2 APPENDIX to Chapter 3 - Overview of statuses and outcomes of CE evaluationes of all EMA approved TCTs in Seria, Scotland and the Netherlands DRUG AND INDICATION SERBIA (RFZO) SCOTLAND (SMC) THE NETHERLANDS (ZiNL) Drug generic name European Medicines Agency (EMA) approved Reimbursement status Pharmacoeconomic assessment Comment Reimbursement status Pharmacoeconomic assessment - ICER [ /] Comment Reimbursement status Pharmacoeconomic assessment - ICER [ /] or cost/unit of time Comment Afatinib patient access scheme (PAS) applied Cost minimisation analysis (CMA) - final outcome not available CMA compared afatinib and erlotinib; afatinib was cost saving when PAS was applied; Exempted from pharmacoeconomic (PE) assessment - If drug's budget impact (BI) crosses, PE assessment can be requested in Axitinib Renal cell carcinoma Cost utility analysis (CUA) - 33,837/ (for treatment after sunitinib); 56,343/ (after cytokine); Despite high ICER, (absence of an alternative and effect on survival) influenced positive decision assessment - Bevacizumab Colorectal R: potentially resectable liver metastases, with stage IVb/c; maximum use of 10 cycles; CUA - 24,000-60,000/ (when added to 5FU regimens); 78,000-93,000/ (when added to irinotecan regimens); Reasons for rejection: high ICER, uncertainties regarding utility estimates, resource use and choice of comparators; assessment - Bevacizumab for the assessment - Bevacizumab Renal cell carcinoma for the gavenegative assessment - Bevacizumab Ovarian for the CUA - 37,749/ high ICER; efficacy data were used from the study where bevacizumab was given in unlicensed dose; assessment - Bevacizumab Breast for the CUA - 77,318/ high ICER; uncertainty regarding extrapolation of overall survival; assessment - Costs analysis (CA), cost/month 4,828 Bortezomib Multiple myeloma prior to ahsct R: for the first line treatment of high risk patients under CUA - 23,077 / R: Use only as triple therapy in combination with dexamethasone and thalidomide, ICER 34,267/ 169
3 Bortezomib Progressive multiple myeloma Bosutinib Chronic myelogenous (CML) Not Brentuximab vedotin Hodgkin lymphoma Not Brentuximab vedotin Anaplastic large cell lymphoma Not Cabozantinib Medullary thyroid Not Carfilzomib Multiple myeloma Not Cetuximab Colorectal Cetuximab Squamous cell of the head and neck Crizotinib Dabrafenib Metastatic melanoma Not Dasatinib Chronic myelogenous Not R: for relapsing patients without polineuropathy R: in metastatic disease with KRAS wild type, after OX/IR regimen; R: (i) locally advanced, inoperable carcinoma; (ii) first line treatment of recurrent disease; for the Not / Not / under and when under Not / CUA - 24,492/ (with ) CUA - ICER varies from dominance to 376,475/ (depending on comparator and phase of disease) CUA - 22,802-26,763/ CUA - 6,870/ CUA - 36,691-42,295/ (without PAS) CUA - 44,456/ for accelarated and 63,727/ for blast phase of the disease PAS meant that manufacturer covers expenses for all patients without response to the treatment; lack of direct comparative efficacy data with any of the comparators; unscertainty on OS gain; high ICER; issued issued R: In metastatic chemotherapy naive patients, with potentially resectable liver metastases; R: Locally advanced disease; Patients not appropriate for chemoradiotherapy, without distant metastases; PAS makes a drug cost effective; ICER with PAS was not publically available; issued high ICER; NICE appraisal superseded earlier SMC decisions; /) /) assessment - assessment - assessment - assessment - assessment - assessment - CA, cost/patient 8,706-8,913 assessment - assessment - assessment - CA, cost/patient/year issued issued 170
4 Dasatinib Acute lymphoblastic (ALL) Denosumab Giant cell tumor of the bone Denosumab Bone metastasis from solid tumors Erlotinib Erlotinib Pancreatic Everolimus Pancreatic neuroendocrine Everolimus Renal cell carcinoma Everolimus Breast Gefitinib Ibritumomab tiuxetan Non-Hodgkin's lymphoma (NHL) Not Not Not for the R: Adenocarcinoma stages IIIb/IV; second line treatment; for the for the for the for the R: NSCLC stage IIIb/ IV, first line treatment for EGFR-TK positive patients; CUA not provided (manufacturer assumed same ICER as for CML ) CUA - with 21,491/ (when ) CUA - 14,562/ (vs. sunitinib); 24,998/ (vs. BSC); CUA - 61,330/; CUA - 28,912/ CUA - 73,827/ (when compared with gemcitabine/carboplatin) CUA - 22,445/ not sufficient economic evidence high ICER; survival gain depends on method used for cross over - high uncertainty; unsecure gain in survival derived from wrong extrapolation; overestimated utility values; high ICER; uncertainty with hazard ratio applied for overall survival; unclear model used in CUA; insufficiently robust ICER; /) assessment - CA, cost/patient/year assessment - CUA available - ICER 37,059/ - 45,791/ (vs. BSC18); cost saving (vs. docetaxel) assessment - assessment - assessment - CA, cost/patient 13,354 assessment - assessment - CA, cost/3 months 6,552 assessment - CA, cost/patient 12,845 issued
5 Ibrutinib Mantle-cell lymphoma Not Ibrutinib Chronic lymphocytic leukaemia (CLL) Not Imatinib GastrointestinaI stromal tumor Imatinib Dermatofibrosarcoma protuberans Not Imatinib Multiple hematologic malignancies (ALL and CML) Ipilimumab Metastatic or unresectable melanoma Not Lapatinib Metastatic breast Nilotinib Chronic myelogenous Obinutuzumab Chronic lymphocytic Not Ofatumumab Chronic lymphocytic Not Panitumumab Colorectal R: Locally advanced inoperable or metastatic disease R: First line treatment in new CML patients, with chronic disease, Philadelphia+ R: Second line metastatic HER2 positive disease, in patients pretreated with antracyclines and/or taxanes and trastuzumab; R: Second line for patients with CML, resistant or intolerant to any previous treatment, including imatinib for the Not / Not / under under Not / CUA - 21,745/ CUA - 20,665/ CUA - 36,118/ (when ) CUA - 24,227/ (vs. trastuzumab), 78,503/ (vs. vinorelbine) and 93,825/ (vs. capecitabine); CUA - 11,000/ (when nilotinib is given in first and imatinib in second line) CUA - 108,815/ issued issued R: patients at high risk of recurrence following complete resection R: in patients at high risk of recurrence following complete resection Despite high ICER, (absence of an alternative and effect on survival) influenced positive decision use of trastuzumab after progression has not been assessed by SMC (inappropriate comparison); other comparisons resulted in unacceptably high ICER; Choice of drugs' (nilotinib, imatinib, dasatinib) sequence largely influences ICER; SMC accepted sequences that would start either with imatinib or with nilotinib; issued Reasons for rejection: high ICER; underestimate of BSC arm survival; /) /) /) assessment - assessment - assessment - assessment - CA, cost/patient/year 84,000 PE concluded that the drug (when prescribed with aromatase inhibitors) has same therapeutic value and less cost compared to trastuzumab assessment - CA, cost/month 4,178 assessment - CA, cost/patient 515, ,000, ICER 45,729/ issued issued R: only HER2 positive patients, given together with aromatase inhibitors; the future; issued 172
6 Pazopanib Renal cell carcinoma Pazopanib Soft tissue sarcoma Pertuzumab Metastatic breast Ponatinib Chronic myelogenous Not Ponatinib Acute lymphoblastic Not Regorafenib Colorectal Not NHL - folicular lymphoma, relapsed/ refractory NHL - folicular lymphoma, previously untreated NHL - folicular lymphoma, stabile disease; induction and maintenance therapy; Reimbursed NHL - diffuse B-cell; in untreated patients; with CHOP regimen; for the for the for the R: restriction actually corresponds with the defined R: restriction actually corresponds with the defined Not mentioned as such, encompassed within two previous s R: Newly diagnosed diffuse B cell lymp. patients (diagnosed as C , C.83.6., C83.9); under and when Not / Not / Not / under under under under CUA - 1,790 (vs sunitinib); 32,988 (vs. BSC) 38,925/ (vs. interferon alfa); CUA - dominates (vs. ifosfamid); 62,856/ (vs. BSC) CUA - 122, ,815/ (depending on compar); CUA - 7,721/ CUA - 7,417-10,472/ CUA - 15,978/ (maintenance phase); Not available (induction phase); CUA - R: only in the first-line treatment of advanced unjustified comarator and uncertainties regarding indirect comparison performed (vs. ifosfamid); high ICER (vs. BSC) High ICER; uncertainty regarding extrapolation of overall survival; although some could apply (survival gain); issued issued issued ; assessment - assessment - assessment - assessment - assessment - assessment -, ICER 27,094/ assessment -, ICER 6,412/ assessment - 173
7 CLL in previously untreated patients; with FC regimen; CLL in previously treated patients; with FC regimen; Sipuleucel-T Prostate Not Sorafenib Hepatocellular carcinoma Sorafenib Renal cell carcinoma Sorafenib Thyroid carcinoma Sunitinib Renal cell carcinoma Sunitinib Gastrointestinal stromal tumour Sunitinib Pancreatic neuroendocrine tumours Temsirolimus Renal cell carcinoma R: restriction actually corresponds with the defined R: if drug (Rx) was not used in the first line, or, if used, patient relapsed >24 months after Rx use; for the for the for the R: First line treatment of locally advanced and/or metastatic disease for the for the for the under under Not / Not / under and when when Not / CUA - 15,593/ CUA - 6,279/ CUA - 67,012/ CUA - 35,523/ CUA - 33,371/ CUA - 27,485/ (when ) CUA- 22,660/ (when ) issued Reasons for rejection: high ICER; insufficiently robust ICER; wrong extrapolation of overall survival; high ICER; issued uncertainty on overall survival gain; high ICER; R: by a physician experienced in the treatment of GIST; could be applied (absence of an alternative and effect on survival); "Decision modifiers" also apply (absence of an alternative and effect on survival); issued to UFAP, under, ICER 15,847-22,191/; to UFAP, under, ICER 15,847-22,191/; Not reimbursed; Rejected by ZiNL assessment - assessment - CA, cost/patient/year assessment - assessment - CA, cost/patient/year 42,105 assessment - CA, cost-saving in comparison to imatinib assessment - CA, cost/patient 27,435 available with US data, ICER $170, ,701/ R: with FCR regimen; Drug should be reassessed 4 years after initial approval; currently under R: with FCR regimen; Drug should be reassessed 4 years after initial approval; currently under Rejected due to lack of clinical evidence 174
8 Temsirolimus Mantle cell lymphoma Trametinib Metastatic melanoma Not Trastuzumab Metastatic breast Reimburssed with restriction Trastuzumab Early breast Reimburssed with restriction Trastuzumab Gastric Trastuzumab emtansine Breast Not Vandetanib Medullary thyroid Not Vemurafenib Metastatic melanoma Vismodegib Basal cell carcinoma Not Ziv-aflibercept Metastatic colorectal Not for the R: first line treatment, in combination with taxanes, 6-8 cycles; monotherapy of trastuzumab therafter until progression; R: (a) as continuation of adjuvant antracyclines based chemotherapy, monoth/w taxanes; (b) locally advanced disease, w taxanes; for the for the Not / under under Not / under and when CMA (s.c. vs. i.v. trasutuzumab) proves s.c. trastuzumab cost saving (no information on i.v. vs. standard therapy) CUA (i.v. trastuzumab vs standard th) - < 3,000/ CUA - 39,644 (vs. 5FU); 41,464/ (vs. capecitabine) CUA - 39,617/ (when ) CUA - 34,623/ ( 27,424/ for subgroup with liver metastases) issued R: (in mbc) excludes its use in combination with an aromatase inhibitor; R: use by breast specialists; Reasons for rejection: high ICER; insufficiently robust ICER; issued "Decision modifiers" applied (absence of an alternative, gain in survival and quality of life); R: for use in the first-line treatment of BRAF metastatic melanoma. Despite high ICER, (gain in survival and defined subgroup that benefits more from the treatment) influenced positive decision /) /) to UFAP, under, under /) assessment - CA cost/patient 36,400-36,800 assessment - CA cost/patient 43,600-44,100;, ICER 86, ,262/ assessment - assessment -, ICER 104,430/ assessment - issued issued R: HER2 positive, metastatic, with FC regimen; Drug should be reassessed 4 years after initial approval; currently under R: only for symtomatic and agressive disease; drug's budget impact already over issued 175
9
National Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationCancer drug approvals for paediatric indications (n=43)
Appendix: Supplementary material [posted as supplied by author] Figure A. Identification of cohort of drugs Total number of antineoplastic and immunomodulating products approved by the EMA up to 31 December
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationLondon Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.
February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationEuropean Experience and Perspective on Assessing Value for Oncology Products. Michael Drummond Centre for Health Economics, University of York
European Experience and Perspective on Assessing Value for Oncology Products Michael Drummond Centre for Health Economics, University of York Outline of Presentation The European landscape on access to
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationGenetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School
Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW
More informationEuropean consortium study on the availability of anti-neoplastic medicines
European consortium study on the availability of anti-neoplastic medicines Nathan I Cherny Alexandru ENIU, MD, PhD Norman Levan Chair in Humanistic Chair, Emerging Countries Committee Medicine Department
More informationNational Cancer Drugs Fund List Ver4.0
National Cancer Drugs Fund List Ver4.0 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Contro VersDate Revision summary Ver 19 Mar 201 Update following Mar-14
More informationNational Cancer Drugs Fund List Ver2.1
National Cancer Drugs Fund List Ver2.1 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Control Version Date Revision summary Ver1.0 19 Mar 2014 Update following
More informationNational Cancer Drugs Fund List Ver4.4
National Cancer Drugs Fund List Ver4.4 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Control Version Date Revision summary Ver1.0 19 Mar 2014 Update following
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationA 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
More informationH&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,
More informationAzacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationDOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
More informationNICE-approved drugs for specialities which fall outside of the services currently provided by the Trust
NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust Drug NICE-approved use NICE TA link Abiraterone Abiraterone Adalimumab Adalimumab Adalimumab Adefovir
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Trastuzumab, as monotherapy and in combination with a taxane, for the treatment of metastatic breast cancer (to include
More informationStratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications
Stratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications Kinga Malottki, Mousumi Biswas, Jon Deeks, Richard Riley, Charles Craddock, Lucinda Billingham
More informationOpening Address: A Quick Survey Thinking 25 Years Backwards & Forwards
Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationCombining Stroma-Targeted Therapies with Radiation to Prevent Resistance
Combining Stroma-Targeted Therapies with Radiation to Prevent Resistance Dan G. Duda, DMD, PhD Harvard Medical School New Cancer Targets NCT Conference Sesptember 23, 2013 Conflicts of Interest None Tumor
More informationTargeted therapies in oncology a Serbian pharmacoeconomic perspective
Targeted therapies in oncology a Serbian pharmacoeconomic perspective Jo a Mihajlo ić 1,2 1 Mihajlo ić Health Analytics; 2 Unit of PharmacoEpidemiology &PharmacoEconomics, University of Groningen Outline
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationMonoclonal Antibodies & Tyrosine-Kinase Inhibitors
Monoclonal Antibodies & Tyrosine-Kinase Inhibitors Charlotte Capstick Clinical Pharmacist Oncology Weston Park Hospital Sheffield Teaching Hospitals NHS Trust Contents Background Dosing Renal impairment
More informationNew Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
More information04 September 2017 Page 1 of 6
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
More informationAvastin (bevacizumab) DRUG.00028, CG-DRUG-68
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationImplementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges
Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges Frédérique Nowak - 21 october 2015 "Putting Science into Standards event:
More informationActive Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
More informationName of firm/applicant
Recommendation:- The 18 th Subject Expert Committee (Oncology & Hematology) deliberated the proposals on 04.07.2014 and recommended the following:- Agenda no. Drug name Name of firm/applicant Recommendations
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationImproving quality of care for patients with ovarian and endometrial cancer Eggink, Florine
University of Groningen Improving quality of care for patients with ovarian and endometrial cancer Eggink, Florine IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if
More informationORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationCENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials CANCER INSTITUTE (36)
CENTER FOR CLINICAL TRIALS St. Luke s Medical Center Ongoing Clinical Trials CANCER INSTITUTE (36) BLOOD TITLE : A Randomized, Two By Two Arm, Multicenter, Open-Label Phase III Study Of BMS-354825 Administered
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1113-6 Program Prior Authorization/Notification Medication Votrient TM (pazopanib) P&T Approval Date 1/12/2010, 9/2010, 12/2010,
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
More informationPharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn
University of Groningen Pharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn IMPORTANT NOTE: You are advised to consult
More informationOur Clinical Trials. Oncology
Our Clinical Trials Oncology ANGIOGENESIS Trebananib (AMG 86) (angiopoietin inhibitor) ANTIBODY DRUG CONJUGATE, continued AMG 595 (anti-egfrviii) Trebananib With Paclitaxel and Trastuzumab or Capecitabine
More informationOpen and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
More informationKeytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
More informationPegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440
This spreadsheet is updated monthly and enables self-audit of a medicines for All guidelines refer to adults unless indicated. No copyright is asserted on this Technology appraisal (TA) Titles are hyperlinks
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationCurrently recruiting trials and/or near future recruitment
Clinical Trials at the Bank of Cyprus Oncology Centre (As of Jan 2018) Currently recruiting trials and/or near future recruitment Development of a module to supplement the EORTC Core instruments for assessment
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1067-7 Program Prior Authorization/Notification Medication Nexavar (sorafenib tosylate) P&T Approval Date 8/2008, 6/2009, 6/2010,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationErlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer
ERRATUM Erlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer This report was commissioned by the NIHR HTA Programme as project number 11/08 Completed 6 th January
More informationMolecular Profiling METASTATIC, REFRACTORY, HER2+, BREAST PHASE 1, METASTATIC, RELAPSED/REFRACTORY, PROSTATE OVARIAN
FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTEMTN AT 513-751- 2273, EXT 27110 Phase 1 REFMAL 381 (Phase 1 open at BAM only)
More informationOral Chemotherapy Agents
Oral Chemotherapy Agents NEW ADVANCES IN TARGETED THERAPY, OVERCOMING BARRIERS AND PROMOTING ADHERENCE KATIE SIAS, PHARMD CLINICAL PHARMACY COORDINATOR HEMATOLOGY/ONCOLOGY MIDMICHIGAN MEDICAL CENTER -
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More informationWorking Formulary January 2013 Oncology Chemotherapy Regimens
Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy
More informationStrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient
StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in
More informationLincolnshire Prescribing and Clinical Effectiveness Bulletin
S Lincolnshire Prescribing and Clinical Effectiveness Bulletin Volume 11 No 12, September 2017 Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: diagnosis and management of colorectal cancer 1.1 Short title Colorectal cancer 2 The remit The Department
More informationRoche setting the standards of cancer care Oncology Event for Investors, June 19
Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time
More informationCancer: Can we Afford the Cure? Current Trends in Oncology Treatment
Cancer: Can we Afford the Cure? Current Trends in Oncology Treatment Julie Kennerly-Shah, PharmD, MS, MHA, BCPS May 30, 2018 The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer
More informationTitle Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Oncofocus Patient Test Report Oncologica UK Ltd, Suite 15-16, The Science Village, Chesterford Research Park, Cambridge, CB10 1XL www.oncologica.com - Tel: +44 (0)1223 785327
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:
Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationDescription The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )
Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationCUP: Treatment by molecular profiling
CUP: Treatment by molecular profiling George Pentheroudakis Professor of Oncology Medical School, University of Ioannina Greece Chair, ESMO Guidelines September 2018 Enterprise Interest No disclosures.
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationOral Oncology/Hematology Reference Indications & Common Dosing Name FDA Indication Compendia Approved Uses Adult Dosing
Oral Oncology/Hematology Reference Indications & Common Dosing Name FDA Indication Compendia Approved Uses Adult Dosing ABIRATERONE Prostate CA: castrate Prostate CA: castrate resistant metastatic dz Prostate
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationMEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT
PAGE 175 PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT Summary of risk management plan for pembrolizumab This is a summary of the risk management plan (RMP) for pembrolizumab. The RMP details
More informationImmunotherapy and Targeted Therapies: The new face of cancer treatment
Immunotherapy and Targeted Therapies: The new face of cancer treatment Abdulazeez Salawu MBBS, MSc, PhD, MRCP Academic Clinical Lecturer Weston Park Hospital, Sheffield Novel Systemic Anti-cancer Therapies
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1101-7 Program Prior Authorization/Notification Medication Sutent (sunitinib malate) P&T Approval Date 8/2008, 6/2009, 6/2010,
More informationClinical Policy: Pazopanib (Votrient) Reference Number: ERX.SPA.139 Effective Date:
Clinical Policy: (Votrient) Reference Number: ERX.SPA.139 Effective Date: 03.01.14 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationNational Horizon Scanning Centre. Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours. August 2008
Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours August 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationMultiple Receptor Tyrosine Kinase Inhibitors
PHARMACY POLICY 5.01.534 Multiple Receptor Tyrosine Kinase Inhibitors Effective Date: Nov. 1, 2018 Last Revised: Oct. 9, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 5.01.517 Use of Vascular Endothelial
More informationErbitux. Erbitux (cetuximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)
More informationBLA /S-048, S-049, S-050, S-051, S-052, S-061, S-062, S-064, S-065, and S-066 SUPPLEMENT APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 BLA 125554/S-048, S-049, S-050, S-051, S-052, S-061, S-062, S-064, S-065, and S-066 SUPPLEMENT APPROVAL Bristol-Myers
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Afinitor, Afinitor Disperz) Reference Number: CP.PHAR.63 Effective Date: 06.01.11 Last Review Date: 08.18 Line of Business: Commercial Coding Implications Revision Log See Important Reminder
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1037-6 Program Prior Authorization/Notification Medication Gleevec (imatinib mesylate) P&T Approval Date 8/2008, 6/2009, 6/2010,
More informationFREEDOM OF INFORMATION SOUTH EAST SCOTLAND CANCER NETWORK
Dear Date 06/02/09 Your Ref Our Ref RM/1220 Enquiries to Richard Mutch Extension 89441 Direct Line 0131-536-9441 Direct Fax 0131-536-9009 Email richard.mutch@lhnhslothian.scot.nhs.uk FREEDOM OF INFORMATION
More informationfor patients with ECOG PS 0-1 as indicated in the CheckMate-067 trial. Upon reconsideration of the Initial Recommendation, perc noted PAG s feedback requesting guidance on extrapolating eligibility to
More informationMedicine Condition being treated NHSGGC Decision Date of decision. 18 June 2018 Page 1 of 5
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Stivarga) Reference Number: CP.CPA.157 Effective Date: 11.16.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationSingle Technology Appraisal (STA) Nivolumab for adjuvant treatment of resected stage III and IV melanoma
Single Technology Appraisal (STA) Nivolumab for adjuvant treatment of resected stage III and IV Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment:
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More information